iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022
07.02.2022 - BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) - iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System, announced today that ...
United States Stephen Kilmer Fastpharming Contract Development Manufacturing Services Bio Inc Glycaneering Development Services
Source: wallstreet-online.de